Literature DB >> 35450352

Novel RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35450352      PMCID： PMC9014428          DOI： 10.1021/acsmedchemlett.2c00059

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Inhibitors Targeting RIPK1/RIPK3: Old and New Drugs.

Authors:  Sofie Martens; Sam Hofmans; Wim Declercq; Koen Augustyns; Peter Vandenabeele
Journal:  Trends Pharmacol Sci       Date:  2020-02-05       Impact factor: 14.819

Review 2.  RIPK1: A rising star in inflammatory and neoplastic skin diseases.

Authors:  Liping Jin; Panpan Liu; Mingzhu Yin; Mi Zhang; Yehong Kuang; Wu Zhu
Journal:  J Dermatol Sci       Date:  2020-06-11       Impact factor: 4.563

Review 3.  The latest information on the RIPK1 post-translational modifications and functions.

Authors:  Qiong Wang; Danping Fan; Ya Xia; Qinbin Ye; Xiaoyu Xi; Guoqiang Zhang; Cheng Xiao
Journal:  Biomed Pharmacother       Date:  2021-08-24       Impact factor: 6.529

Review 4.  Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment.

Authors:  Shang Li; Lailiang Qu; Xiaobing Wang; Lingyi Kong
Journal:  Pharmacol Ther       Date:  2021-09-02       Impact factor: 12.310

Review 5.  25 years of research put RIPK1 in the clinic.

Authors:  Lin Liu; Najoua Lalaoui
Journal:  Semin Cell Dev Biol       Date:  2020-09-13       Impact factor: 7.727

Review 6.  The role of necroptosis in disease and treatment.

Authors:  Xiaoxiao Liu; Xin Xie; Yuanyuan Ren; Zhiying Shao; Nie Zhang; Liantao Li; Xin Ding; Longzhen Zhang
Journal:  MedComm (2020)       Date:  2021-12-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.